HARCP

HEROIN ADDICTION AND
RELATED CLINICAL PROBLEMS

The official journal of
EUROPAD - European Opiate Addiction Treatment Association
WFTOD - World Federation for the Treatment of Opioid Dependence
Editor: Icro Maremmani, MD - Pisa, Italy, EU
Associate Editors:
Thomas Clausen, MD - Oslo, Norway
Pier Paolo Pani, MD - Cagliari, Italy, EU
Marta Torrens, MD - Barcelona, Spain, EU
Statistical Editor:
Mario Miccoli, PhD - Pisa, Italy, EU

HARCP Archives

Browse by article Browse by volume    

Heroin Addiction and Related Clinical Problems: 2026, 28: 231-234

Balancing Addiction Treatment and Road Safety: The Swiss Consensus Guidelines on Opioid Agonist Therapy and Fitness-to-Drive

Cristian Palmiere

Digital Object Identifier:
https://doi.org/10.62401/2531-4122-2026-27

Summary: Background: Opioid agonist therapy (OAT) represents the first-line treatment for opioid use disorder. While stable OAT controls clinical symptoms to maintain functional capacities, traffic regulations require strict oversight regarding fitness-to-drive. Historically, regulatory ambiguity created barriers between public safety and patient reintegration. This paper outlines the 2024 joint consensus guidelines issued by the Swiss Society of Legal Medicine (SSML) and the Society of Addiction Medicine (SSAM) for OAT and fitness-to-drive medical assessment. Methods: A multidisciplinary working group from SSML and SSAM harmonised national legal frameworks with modern addiction standards. The present manuscript was prepared as a critical commentary and independent synthesis to contextualise these national regulatory developments within the broader international discourse on addiction, traffic safety, and social stigma reduction. Results: The guidelines establish a framework for traffic medicine assessment. Key criteria include: (1) a stable OAT regimen (methadone, levomethadone, buprenorphine, or slow-release oral morphine) for six or more months without illicit co-consumption; (2) exclusion of diacetylmorphine maintenance and Group 2 licenses; (3) strict regulation of concurrent psychotropics, permitted case-by-case via traffic medicine evaluation; (4) mandatory toxicological monitoring supervised by traffic medicine experts, including cannabis screening and semestral hair analyses for up to 3 years; and (5) low-risk alcohol limits. Prescribing physicians retain responsibilities regarding temporary driving abstention and reporting safety risks. Traffic medicine experts retain discretion to depart from directives in documented cases. Conclusions: The SSML/SSAM guidelines provide an evidence-based paradigm reconciling road safety mandates with clinical stabilisation goals, actively dismantling treatment-related stigma and promoting social reintegration.

Keywords: Opioid Agonist Therapy; Fitness-to-Drive Medical Assessment; Traffic Medicine; Toxicology

 

EUROPAD - European Opiate Addiction Treatment Association
Brussels, Belgium, EU
P. IVA 01681650469 – Codice Fiscale 94002580465 Reserved Area
Tel/Phone: 0584 - 790073 - Email: info@heroinaddictionrelatedclinicalproblems.org
Start of page